Histone deacetylase inhibitors inhibit lung adenocarcinoma metastasis via HDAC2/YY1 mediated downregulation of Cdh1

Sci Rep. 2023 Jul 26;13(1):12069. doi: 10.1038/s41598-023-38848-6.

Abstract

Metastasis is a leading cause of mortality in patients with lung adenocarcinoma. Histone deacetylases have emerged as promising targets for anti-tumor drugs, with histone deacetylase inhibitors (HDACi) being an active area of research. However, the precise mechanisms by which HDACi inhibits lung cancer metastasis remain incompletely understood. In this study, we employed a range of techniques, including qPCR, immunoblotting, co-immunoprecipitation, chromatin-immunoprecipitation, and cell migration assays, in conjunction with online database analysis, to investigate the role of HDACi and HDAC2/YY1 in the process of lung adenocarcinoma migration. The present study has demonstrated that both trichostatin A (TSA) and sodium butyrate (NaBu) significantly inhibit the invasion and migration of lung cancer cells via Histone deacetylase 2 (HDAC2). Overexpression of HDAC2 promotes lung cancer cell migration, whereas shHDAC2 effectively inhibits it. Further investigation revealed that HDAC2 interacts with YY1 and deacetylates Lysine 27 and Lysine9 of Histone 3, thereby inhibiting Cdh1 transcriptional activity and promoting cell migration. These findings have shed light on a novel functional mechanism of HDAC2/YY1 in lung adenocarcinoma cell migration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / enzymology
  • Adenocarcinoma of Lung* / metabolism
  • Adenocarcinoma of Lung* / pathology
  • Animals
  • Antigens, CD* / metabolism
  • Butyric Acid / pharmacology
  • Butyric Acid / therapeutic use
  • Cadherins* / genetics
  • Cadherins* / metabolism
  • Cell Movement / drug effects
  • Epithelial-Mesenchymal Transition / drug effects
  • Female
  • Gene Expression Regulation, Neoplastic
  • Histone Deacetylase 2* / antagonists & inhibitors
  • Histone Deacetylase 2* / metabolism
  • Histone Deacetylase Inhibitors* / pharmacology
  • Histone Deacetylase Inhibitors* / therapeutic use
  • Humans
  • Mice
  • Neoplasm Metastasis* / drug therapy
  • Neoplasm Metastasis* / pathology
  • Neoplasm Metastasis* / prevention & control
  • Protein Binding
  • Transcription, Genetic
  • Transforming Growth Factor beta / metabolism
  • YY1 Transcription Factor* / metabolism

Substances

  • Histone Deacetylase Inhibitors
  • HDAC2 protein, human
  • YY1 protein, human
  • CDH1 protein, human
  • trichostatin A
  • Butyric Acid
  • Transforming Growth Factor beta
  • Histone Deacetylase 2
  • YY1 Transcription Factor
  • Cadherins
  • Antigens, CD